United States
Summary
This biopharmaceutical company specializes in developing innovative therapies for rare diseases, focusing on conditions such as Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and Huntington's Disease. They utilize advanced scientific platforms to create treatments that address the underlying causes of these diseases, aiming to improve the quality of life for patients and extend their moments with loved ones. The company is committed to clinical research and has a robust pipeline of therapies, including the first approved treatment for Duchenne and gene therapies.
Based on content on ptcbio.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
24.0 years — Since Jan 2001
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Biopharmaceuticals focused on rare diseases.
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Microsoft
TXT Record
Adobe identity provider
TXT Record
Apple
TXT Record
Autodesk
TXT Record
DocuSign
TXT Record
TXT Record
Intersight
TXT Record
Mandrill
TXT Record
OneTrust
TXT Record
Salesforce
TXT Record
Mimecast
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2001 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2002 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2003 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2004 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2005 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2010 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2011 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|